Sustainability Report

Overview

The report describes Immedica's 2025 progress in expanding access to rare-disease therapies, including approvals for Ravicti and Zepzelca and continued Loargys development. It highlights strengthened ESG governance through an ESG Committee reporting to the Board, alongside a global Great Place To Work Trust Index score of 93%. The company reports 22.3 tCO2 Scope 1, 0.71 tCO2 Scope 2 and 21,534.9 tCO2 Scope 3 emissions, with 2024 restated after a carbon-accounting software change. It also reports SBTi-submitted near-term targets of 42% Scope 1 and 2 reduction and 51,6% Scope 3 intensity reduction by 2030, pending validation.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services